The AKT inhibitor capivasertib (AZD5363) inhibited AKT activation and resensitized saracatinib-resistant HNSCC cells to saracatinib.314 Capivasertib in combination with saracatinib inhibited tumor proliferation more efficiently than either agent in xenografts. The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.